Semaglutide reduced C-reactive protein levels by 43% compared to 10% with placebo (OR 0.64) in a pooled analysis of obese patients with heart failure with preserved ejection fraction.
Do GLP-1 receptor agonists improve quality of life and reduce inflammation in obese patients with HFpEF?
GLP-1 receptor agonists like semaglutide show promise in managing HFpEF in obese patients by targeting underlying inflammatory processes, improving quality of life, and reducing CRP levels.
Effect estimate: OR 0.64 (95% CI 0.56 to 0.72)
Absolute Event Rate: -43% vs -10%
p-value: p=<0.001
Heart Failure with Preserved Ejection Fraction (HFpEF) represents a significant challenge in modern cardiovascular medicine, characterized by diastolic dysfunction and a chronic pro-inflammatory milieu. The high prevalence of comorbidities such as diabetes, visceral obesity, and aging, which contribute to systemic inflammation, plays a pivotal role in the pathogenesis and progression of HFpEF. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs), a class of glucose-lowering drugs, have demonstrated a wide range of pleiotropic effects that extend beyond glycaemic control. These effects include the reduction of inflammation and oxidative stress, vasodilation, decreased arterial stiffness, and a reduction in myocardial fibrosis-key factors in the pathophysiology of HFpEF. Recent evidence from the STEP-HFpEF and STEP-HFpEF-DM trials provides the first robust data supporting the efficacy of GLP-1 RAs, specifically semaglutide, in improving the quality of life in obese patients with HFpEF. These trials also demonstrated a significant reduction in C-Reactive Protein (CRP) levels, reinforcing the hypothesis that suppressing the pro-inflammatory state may yield substantial clinical benefits in this patient population. These findings suggest that GLP-1 RAs could play a crucial role in the management of HFpEF, particularly in patients with obesity, by targeting the underlying inflammatory processes and contributing to better overall cardiovascular outcomes.
Bonfioli et al. (Sat,) conducted a review in Heart Failure with Preserved Ejection Fraction (HFpEF). GLP-1 receptor agonists (semaglutide) vs. Placebo was evaluated on C-Reactive Protein (CRP) reduction (OR 0.64, 95% CI 0.56 to 0.72, p=<0.001). Semaglutide reduced C-reactive protein levels by 43% compared to 10% with placebo (OR 0.64) in a pooled analysis of obese patients with heart failure with preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: